Earnings4554Fuji Pharma Co.,Ltd.
Fuji Pharma Reports Q3 Revenue of 45.4 billion, Up 23%
TOKYO, Aug 06 (Pulse News Wire) – Fuji Pharma Co., Ltd. (4554.T) reported consolidated results for Q3 FY2026 (ending September 2026).
Revenue was ¥45.4 billion (+22.8% YoY). operating profit was ¥5,394 million (+60.2%). net profit attributable to shareholders was ¥1,820 million (-0.6%).
Total assets stood at ¥98.4 billion with an equity ratio of 52.7%. The company declared an annual dividend of ¥26 per share. The full-year forecast for the current fiscal year is revenue of ¥59.2 billion (+14.7%).
Financial results — FY2026/9 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥45,382M | +22.8% |
| Operating profit | ¥5,394M | +60.2% |
| Net profit | ¥1,820M | -0.6% |
Next period forecast
Revenue
¥59,250M
+14.7%Op. profit
¥6,120M
+22.6%Net profit
¥2,240M
-25.3%Figures in millions of yen
End of article